It will surpass $100 within 18 months and chum you will be so jealous you will have to seek counselling. No worries on my part. All of your conjecture and lack of knowledge will just add fuel to your jealousy. You will be in a bad Karma mode. t
Several companies are interested in the drug for promoting it. In recent lecture Dr. P. M. from SC noted that there are more HoF patient than we originally thought. There are 1 per 250K patients that have HoF, and one in 250 patients have HeF. The market is bigger than originally thought. On top of that ONLY Mipo showed an eight fold reduction in CV disease after two years on the drug in the hardest to treat population in the universe. That being the HoF patient population. The competitor has not been able to show ANY reduction in CV events after three years of real world use and data. t
With a name like tudy you sure sound like a girl!! That is OK chum, you could play the part of the female in the video Thriller for the rest of the chums. You don't keep up or know anything about biotech. Keep plugging the donkey vicl. They did get some good news the other day.....that being that vj may have being able to get out of all those lawsuits that he created by delaying data back in 2013 for that donkey drug that where the placebo group did better than the treatment group and they had better safety too. Some company that vicl. t
I think that Mr. Putin isn't saying anything untrue in regards to how hard it is to make money investing in biotech. He also isn't sayiing anthing really new. People who do their research realize that 99.2% of all drugs for Alzheimer disease will fail, about 95% of all CA drugs will fail. Getting a drug to phase III is almost impossible. But there are those REGN's and PCYC's that make the effort worth it. But you have to reallly scope down and pick your target and learn as much as you can. That alone doesn't guarantee success either, but for those that can tolerate the risk the effort can be worth it. Thank you Mr. Putin. t
Immunomedics: FDA grants Breakthrough Therapy Designation for sacituzumab govitecan (1.82)
Immunomedics's lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least 2 prior therapies for metastatic disease.
The Breakthrough Therapy Designation was supported by a Phase 2 study in patients with metastatic TNBC who had received a median of 5 prior therapies